Trial Profile
De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2014
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 22 Oct 2011 Interim results presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 04 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Jun 2010 New trial record